---
title: Viatris (VTRS) — intrinsic value and fair price
canonical: https://sweetvaluelab.com/stocks/vtrs
ticker: VTRS
as_of: 2026-10-17
sector: Healthcare
industry: Drug Manufacturers - Specialty & Generic
---
# Viatris (VTRS)

Viatris (VTRS) closed at $18.66 on Oct 16, 2026, overvalued by 81% vs its model value of $10.30 (from its peers' median EV/Revenue).

## Key figures

| Figure | Value |
| --- | ---: |
| Last close | $18.66 (Oct 16, 2026) |
| Model value (from its peers' median EV/Revenue) | $10.30 |
| Price vs model | overvalued by 81% vs model |
| Range of that model | $4.74 – $25.90 |
| Market value | $21.4B |
| P/E (fiscal 2025) | — |
| Net margin (fiscal 2025) | -24.6% |
| Free cash flow (fiscal 2025) | $1.9B |
| Dividend yield (trailing twelve months) | 2.57% |
| Beta | 0.86 |
| Cost of capital (WACC) | 7.23% |
| Business classification | Loss-Making (Revenue declining (~-4% recent), Currently unprofitable, Highly cyclical earnings, Strong FCF yield (9.0%)) |

## On the stock lists

| List | Place | Figure | Page |
| --- | ---: | ---: | --- |
| Highest free cash flow yield | #46 | 9.0% | https://sweetvaluelab.com/lists/highest-free-cash-flow-yield |
| Near 52-week highs | #23 | 0.0% | https://sweetvaluelab.com/lists/near-52-week-highs |
| Best performing this year | #45 | +49.9% | https://sweetvaluelab.com/lists/best-performing-this-year |

## Dividends

| Figure | Value |
| --- | ---: |
| Trailing dividend yield | 2.57% |
| Dividends per share, last 12 months | $0.48 |
| Coverage | — |
| Raised | — |
| Growth over 4 years | 0.5% a year |
| Latest payment | $0.12, ex-date Aug 21, 2026, paid Sep 16, 2026 |

| Year of payments | Dividends per share |
| --- | ---: |
| To Aug 23, 2022 | $0.47 |
| To Aug 23, 2023 | $0.48 |
| To Aug 23, 2024 | $0.48 |
| To Aug 22, 2025 | $0.48 |
| Trailing twelve months (to Aug 21, 2026) | $0.48 |

## Valuation models

Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 17, 2026.

| Model | Role | Value per share | Low | High |
| --- | --- | ---: | ---: | ---: |
| DCF · Perpetuity growth · 5y | primary | $0.00 | $0.00 | $0.00 |
| DCF · Perpetuity growth · 10y | cross check | $0.00 | $0.00 | $0.00 |
| DCF · EBITDA exit · 5y | cross check | $0.00 | $0.00 | $0.00 |
| DCF · EBITDA exit · 10y | cross check | $0.00 | $0.00 | $0.00 |
| EV/EBITDA · peers | cross check | $0.00 | $0.00 | $0.00 |
| EV/Revenue · peers | cross check | $10.30 | $4.74 | $25.90 |
| Earnings power value | cross check | $0.00 | $0.00 | $0.00 |
| Dividend discount | cross check | $0.00 | $0.00 | $0.00 |

## Insider activity (SEC Form 4)

No open-market insider buys or sales filed in the past 90 days.

| Date | Insider | Relationship | Transaction | Shares | Value |
| --- | --- | --- | --- | ---: | ---: |
| Sep 30, 2026 | Groothuis Leo Frans | Director | Grant / award | 2,469 | $43,750.7 |
| Sep 30, 2026 | SIMMONS DAVID S | Director | Grant / award | 2,117 | $37,513.2 |
| Aug 15, 2026 | Enrietti Andrew | See Remarks | Tax withholding | 10,931 | $177,410.1 |
| Aug 15, 2026 | Enrietti Andrew | See Remarks | Option/RSU exercise | 999 | $0 |
| Aug 15, 2026 | Enrietti Andrew | See Remarks | Tax withholding | 435 | $7,060.1 |

## Recent SEC filings

| Filed | Form | What | Filing |
| --- | --- | --- | --- |
| Oct 8, 2026 | 8-K | 1.01 Entry into a Material Agreement; 8.01 Other Events; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1792044/000114036126039024/ef20083514_8k.htm |
| Aug 6, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/1792044/000179204426000041/vtrs-20260630.htm |
| Aug 6, 2026 | 8-K | 2.02 Results of Operations (Earnings); 8.01 Other Events; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1792044/000179204426000037/vtrs-20260806.htm |
| Jul 1, 2026 | 8-K | 1.01 Entry into a Material Agreement; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1792044/000114036126027216/ef20077152_8k.htm |
| Jun 18, 2026 | 8-K | 1.01 Entry into a Material Agreement; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/1792044/000114036126025744/ef20076340_8k.htm |

## Superinvestors holding it (latest 13F)

| Manager | Quarter | Shares | Value |
| --- | --- | ---: | ---: |
| Christopher Davis | 2026-06-30 | 75,232,254 | $1.2B |
| Einhorn | 2026-06-30 | 2,773,470 | $44.0M |
| Bridgewater | 2026-06-30 | 1,698,341 | $27.0M |
| Bill Miller | 2026-06-30 | 733,164 | $11.6M |

4 tracked managers in all.

## About

Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics,…

---

Source: https://sweetvaluelab.com/stocks/vtrs (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.